Published in Vaccine Weekly, April 3rd, 2002
The new company, Celltrion, will be established by the end of next year with two Korean companies and the state-run Korea Tobacco and Ginseng Corp., South Korea's Ministry of Commerce, Industry and Energy said in a statement.
The $150 million plant will be built in an industrial complex in Incheon, west of Seoul.
Under the plan, San Francisco-based VaxGen will own 45% of the venture, and the rest will be held by South Korea's Nexol Biotech Co., J. Stephen &...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly